These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
106 related articles for article (PubMed ID: 7397942)
1. Pharmacokinetics of 1-alkylcarbamoyl-5-fluorouracils in plasma and ascites fluid after oral administration in mice. Iigo M; Hoshi A; Kuretani K Cancer Chemother Pharmacol; 1980; 4(3):189-93. PubMed ID: 7397942 [TBL] [Abstract][Full Text] [Related]
2. Metabolic fate on 1-hexylcarbamoyl-5-fluorouracil and 5-fluorouracil in mice bearing ascites sarcoma 180. Iigo M; Kuretani K; Hoshi A J Natl Cancer Inst; 1981 Feb; 66(2):345-9. PubMed ID: 6935483 [TBL] [Abstract][Full Text] [Related]
3. Antitumor activity of 1-alkylcarbamoyl derivatives of 5-fluorouracil in a variety of mouse tumors. Iigo M; Hoshi A; Nakamura A; Kuretani K Cancer Chemother Pharmacol; 1978; 1(4):203-8. PubMed ID: 750108 [TBL] [Abstract][Full Text] [Related]
4. Relationship between antitumor effect and metabolites of 5-fluorouracil in combination treatment with 5-fluorouracil and guanosine in ascites sarcoma 180 tumor system. Iigo M; Kuretani K; Hoshi A Cancer Res; 1983 Dec; 43(12 Pt 1):5687-94. PubMed ID: 6640523 [TBL] [Abstract][Full Text] [Related]
5. 5-Fluorouracil derivatives. XXII. Synthesis and antitumor activities of 1-carbamoyl-5-fluorouracils. Ozaki S; Kong X; Watanabe Y; Hoshiko T; Koga T; Ogasawara T; Takizawa T; Fujisawa H; Iigo M; Hoshi A Chem Pharm Bull (Tokyo); 1997 Aug; 45(8):1372-5. PubMed ID: 9301037 [TBL] [Abstract][Full Text] [Related]
6. Antitumor activity of 1-alkoxycarbonylalkylcarbamoyl-5-fluorouracil derivatives by oral administration. Iigo M; Hoshi A; Inomata M; Ando N; Kuretani K J Pharmacobiodyn; 1981 Mar; 4(3):203-10. PubMed ID: 7252769 [TBL] [Abstract][Full Text] [Related]
7. Antitumor activity of BOF-A2, a new 5-fluorouracil derivative. Fujii S; Fukushima M; Shimamoto Y; Ohshimo H; Imaoka T; Shirasaka T Jpn J Cancer Res; 1989 Feb; 80(2):173-81. PubMed ID: 2498252 [TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of oxaliplatin in gastrointestinal cancer patients with malignant ascites. Kochi M; Fujii M; Kanamori N; Kaiga T; Okubo R; Mihara Y; Takayama T J Chemother; 2011 Feb; 23(1):28-31. PubMed ID: 21482491 [TBL] [Abstract][Full Text] [Related]
9. Antitumor activity of metabolites of 1-hexylcarbamoyl-5-fluorouracil and related compounds against L1210 leukemia in vivo and L5178Y lymphoma cells in vitro. Hoshi A; Yoshida M; Inomata M; Iigo M; Ando N; Kuretani K J Pharmacobiodyn; 1980 Sep; 3(9):478-81. PubMed ID: 7463306 [TBL] [Abstract][Full Text] [Related]
10. Intestinal absorption of 5-fluorouracil and its alkylcarbamoyl derivatives in the rat small intestine. Sasaki H; Takahashi T; Nakamura J; Konishi R; Shibasaki J J Pharm Sci; 1986 Jul; 75(7):676-9. PubMed ID: 3761169 [TBL] [Abstract][Full Text] [Related]
11. Antitumor activity of 1-hexylcarbamoyl-5-fluorouracil in a variety of experimental tumors. Hoshi A; Iigo M; Nakamura A; Yoshida M; Kuretani K Gan; 1976 Oct; 67(5):725-31. PubMed ID: 1017587 [TBL] [Abstract][Full Text] [Related]
12. Development of novel 5-fluorouracil carrier erythrocyte with pharmacokinetics and potent antitumor activity in mice bearing malignant ascites. Wang GP; Guan YS; Jin XR; Jiang SS; Lu ZJ; Wu Y; Li Y; Li M; Luo F J Gastroenterol Hepatol; 2010 May; 25(5):985-90. PubMed ID: 20546454 [TBL] [Abstract][Full Text] [Related]
13. Prolonged treatment schedules with intraperitoneal 5-fluorouracil diminish the local-regional nature of drug distribution. Sugarbaker PH; Klecker RW; Gianola FJ; Speyer JL Am J Clin Oncol; 1986 Feb; 9(1):1-7. PubMed ID: 3953487 [TBL] [Abstract][Full Text] [Related]
15. Antitumor activity of two novel low immunosuppressive fluoropyrimidines UK-21 and UK-25. Sakamoto O; Mori H; Kitaichi K; Koda A; Kato T Jpn J Pharmacol; 1992 Aug; 59(4):469-76. PubMed ID: 1434142 [TBL] [Abstract][Full Text] [Related]
16. Demonstration of hepatic triglyceride lipase-like activity in ascites fluid of mice with sarcoma 180. Masuno H; Okuda H Eur J Cancer Clin Oncol; 1985 Jun; 21(6):727-32. PubMed ID: 4018114 [TBL] [Abstract][Full Text] [Related]
17. 5-Fluorouracil derivatives. IV. Synthesis of antitumor-active acyloxyalkyl-5-fluorouracils. Ozaki S; Watanabe Y; Hoshiko T; Mizuno H; Ishikawa K; Mori H Chem Pharm Bull (Tokyo); 1984 Feb; 32(2):733-8. PubMed ID: 6733816 [No Abstract] [Full Text] [Related]
18. Effect of coadministration of uracil or cytosine on the anti-tumor activity of clinical doses of 1-(2-tetrahydrofuryl)-5-fluorouracil and level of 5-fluorouracil in rodents. Fujii S; Kitano S; Ikenaka K; Shirasaka T Gan; 1979 Apr; 70(2):209-14. PubMed ID: 381088 [TBL] [Abstract][Full Text] [Related]
19. 5-Fluorouracil derivatives. XII. Synthesis and antitumor activity of alpha-alkylthiomethyl-, alpha-alkylsulfinylmethyl-, alpha-alkylsulfonylmethyl-, and alpha-acylthiomethyl-5-fluorouracils. Ozaki S; Nagase T; Tamai H; Mori H; Hoshi A; Iigo M Chem Pharm Bull (Tokyo); 1987 Sep; 35(9):3894-7. PubMed ID: 3435984 [No Abstract] [Full Text] [Related]
20. Antitumor activity of 1-acyloxymethyl derivatives of 5-fluorouracil against L1210 leukemia. Hoshi A; Inomata M; Kanzawa F; Iigo M; Kuretani K J Pharmacobiodyn; 1982 Mar; 5(3):208-12. PubMed ID: 7097489 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]